Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis
Polypharmacy (intake of ≥5 drugs) is an important issue for patients with chronic diseases such as multiple sclerosis (MS). We aimed to assess the prevalence of polypharmacy with regard to the severity of anxiety/depression and to comorbidities. Therefore, 374 MS patients from two German neurologica...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/16/5379 |
| _version_ | 1797435910885736448 |
|---|---|
| author | Julia Baldt Niklas Frahm Michael Hecker Barbara Streckenbach Silvan Elias Langhorst Pegah Mashhadiakbar Katja Burian Janina Meißner Felicita Heidler Jörg Richter Uwe Klaus Zettl |
| author_facet | Julia Baldt Niklas Frahm Michael Hecker Barbara Streckenbach Silvan Elias Langhorst Pegah Mashhadiakbar Katja Burian Janina Meißner Felicita Heidler Jörg Richter Uwe Klaus Zettl |
| author_sort | Julia Baldt |
| collection | DOAJ |
| description | Polypharmacy (intake of ≥5 drugs) is an important issue for patients with chronic diseases such as multiple sclerosis (MS). We aimed to assess the prevalence of polypharmacy with regard to the severity of anxiety/depression and to comorbidities. Therefore, 374 MS patients from two German neurological sites were examined for drug burden, comorbidities, disability level and psychopathological measures capturing depression and anxiety using the Hospital Anxiety and Depression Scale (HADS-A and HADS-D). We found that patients with a higher HADS-D score take more medication (r = 0.217, <i>p</i> < 0.001). Furthermore, patients with higher depression severity were more likely to show polypharmacy (<i>p</i> < 0.001). These differences were not significant for anxiety. (<i>p</i> = 0.413). Regarding the frequency of ≥1 comorbidities, there were no significant differences between patients with different HADS-A (<i>p</i> = 0.375) or HADS-D (<i>p</i> = 0.860) severity levels, whereas the concrete number of comorbidities showed a significant positive linear correlation with HADS-A (r = 0.10, <i>p</i> = 0.045) and HADS-D scores (r = 0.19, <i>p</i> < 0.001). In conclusion, symptoms of depression pose a relevant issue for MS patients and are correlated with polypharmacy and comorbidities. Anxiety is not correlated with polypharmacy but with the frequency of several comorbidity groups in MS patients. |
| first_indexed | 2024-03-09T10:55:04Z |
| format | Article |
| id | doaj.art-31af93b4fcdb4fac9694353f744d4704 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T10:55:04Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-31af93b4fcdb4fac9694353f744d47042023-12-01T01:43:54ZengMDPI AGJournal of Clinical Medicine2077-03832023-08-011216537910.3390/jcm12165379Depression and Anxiety in Association with Polypharmacy in Patients with Multiple SclerosisJulia Baldt0Niklas Frahm1Michael Hecker2Barbara Streckenbach3Silvan Elias Langhorst4Pegah Mashhadiakbar5Katja Burian6Janina Meißner7Felicita Heidler8Jörg Richter9Uwe Klaus Zettl10Section of Neuroimmunology, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, GermanySection of Neuroimmunology, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, GermanySection of Neuroimmunology, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, GermanySection of Neuroimmunology, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, GermanySection of Neuroimmunology, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, GermanySection of Neuroimmunology, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, GermanySection of Neuroimmunology, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, GermanySection of Neuroimmunology, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, GermanyEcumenic Hainich Hospital GmbH, 99974 Mühlhausen, GermanyEcumenic Hainich Hospital GmbH, 99974 Mühlhausen, GermanySection of Neuroimmunology, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, GermanyPolypharmacy (intake of ≥5 drugs) is an important issue for patients with chronic diseases such as multiple sclerosis (MS). We aimed to assess the prevalence of polypharmacy with regard to the severity of anxiety/depression and to comorbidities. Therefore, 374 MS patients from two German neurological sites were examined for drug burden, comorbidities, disability level and psychopathological measures capturing depression and anxiety using the Hospital Anxiety and Depression Scale (HADS-A and HADS-D). We found that patients with a higher HADS-D score take more medication (r = 0.217, <i>p</i> < 0.001). Furthermore, patients with higher depression severity were more likely to show polypharmacy (<i>p</i> < 0.001). These differences were not significant for anxiety. (<i>p</i> = 0.413). Regarding the frequency of ≥1 comorbidities, there were no significant differences between patients with different HADS-A (<i>p</i> = 0.375) or HADS-D (<i>p</i> = 0.860) severity levels, whereas the concrete number of comorbidities showed a significant positive linear correlation with HADS-A (r = 0.10, <i>p</i> = 0.045) and HADS-D scores (r = 0.19, <i>p</i> < 0.001). In conclusion, symptoms of depression pose a relevant issue for MS patients and are correlated with polypharmacy and comorbidities. Anxiety is not correlated with polypharmacy but with the frequency of several comorbidity groups in MS patients.https://www.mdpi.com/2077-0383/12/16/5379multiple sclerosisdepressionanxietypolypharmacycomorbiditytherapy switches |
| spellingShingle | Julia Baldt Niklas Frahm Michael Hecker Barbara Streckenbach Silvan Elias Langhorst Pegah Mashhadiakbar Katja Burian Janina Meißner Felicita Heidler Jörg Richter Uwe Klaus Zettl Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis Journal of Clinical Medicine multiple sclerosis depression anxiety polypharmacy comorbidity therapy switches |
| title | Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis |
| title_full | Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis |
| title_fullStr | Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis |
| title_full_unstemmed | Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis |
| title_short | Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis |
| title_sort | depression and anxiety in association with polypharmacy in patients with multiple sclerosis |
| topic | multiple sclerosis depression anxiety polypharmacy comorbidity therapy switches |
| url | https://www.mdpi.com/2077-0383/12/16/5379 |
| work_keys_str_mv | AT juliabaldt depressionandanxietyinassociationwithpolypharmacyinpatientswithmultiplesclerosis AT niklasfrahm depressionandanxietyinassociationwithpolypharmacyinpatientswithmultiplesclerosis AT michaelhecker depressionandanxietyinassociationwithpolypharmacyinpatientswithmultiplesclerosis AT barbarastreckenbach depressionandanxietyinassociationwithpolypharmacyinpatientswithmultiplesclerosis AT silvaneliaslanghorst depressionandanxietyinassociationwithpolypharmacyinpatientswithmultiplesclerosis AT pegahmashhadiakbar depressionandanxietyinassociationwithpolypharmacyinpatientswithmultiplesclerosis AT katjaburian depressionandanxietyinassociationwithpolypharmacyinpatientswithmultiplesclerosis AT janinameißner depressionandanxietyinassociationwithpolypharmacyinpatientswithmultiplesclerosis AT felicitaheidler depressionandanxietyinassociationwithpolypharmacyinpatientswithmultiplesclerosis AT jorgrichter depressionandanxietyinassociationwithpolypharmacyinpatientswithmultiplesclerosis AT uweklauszettl depressionandanxietyinassociationwithpolypharmacyinpatientswithmultiplesclerosis |